RSLS - ReShape Lifesciences Inc. Stock Price, Fair Value and News

0.18USD+0.01 (+5.88%)Market Closed

Market Summary

USD0.18+0.01

Market Closed

5.88%

RSLS Stock Price

View Fullscreen

RSLS RSI Chart

RSLS Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.39

Price/Sales (Trailing)

0.51

EV/EBITDA

-0.16

Price/Free Cashflow

-0.3

RSLS Price/Sales (Trailing)

RSLS Profitability

Operating Margin

64.61%

EBT Margin

-130.37%

Return on Equity

-240.8%

Return on Assets

-132.64%

Free Cashflow Yield

-330.89%

RSLS Fundamentals

RSLS Revenue

Revenue (TTM)

8.3M

Rev. Growth (Yr)

-15%

Rev. Growth (Qtr)

-1.92%

RSLS Earnings

Earnings (TTM)

-10.9M

Earnings Growth (Yr)

17.62%

Earnings Growth (Qtr)

-29.15%

Breaking Down RSLS Revenue

Last 7 days

5.9%

Last 30 days

12.5%

Last 90 days

5.9%

Trailing 12 Months

-92.6%

How does RSLS drawdown profile look like?

RSLS Financial Health

Current Ratio

2.24

Debt/Equity

0.09

Debt/Cashflow

-32.49

RSLS Investor Care

Shares Dilution (1Y)

697.23%

Diluted EPS (TTM)

-0.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.3M	0	0	0
2023	11.1M	10.4M	9.8M	8.7M
2022	12.8M	12.2M	11.3M	11.2M
2021	12.7M	14.6M	14.7M	13.6M
2020	2.3M	3.6M	6.9M	10.3M
2019	9.5M	7.2M	4.5M	3.3M
2018	9.7M	10.5M	10.7M	9.1M
2017	3.8M	5.0M	7.0M	9.9M
2016	4.2M	3.9M	3.6M	3.4M
2015	3.7M	3.8M	3.9M	4.0M
2014	0	0	0	3.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ReShape Lifesciences Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 25, 2023	stankovich thomas	sold	-35.37	0.27	-131	chief financial officer
Oct 11, 2023	stankovich thomas	sold	-36.27	0.93	-39.00	chief financial officer
Sep 01, 2023	stankovich thomas	sold	-105	0.89	-118	chief financial officer
Aug 24, 2023	stankovich thomas	sold	-55.38	1.42	-39.00	chief financial officer
Aug 04, 2023	stankovich thomas	sold	-154	1.43	-108	chief financial officer
Jul 06, 2023	stankovich thomas	sold	-155	1.47	-106	chief financial officer
Jun 30, 2023	stankovich thomas	bought	26,907	1.52	17,702	chief financial officer
May 31, 2023	stankovich thomas	sold	-236	2.41	-98.00	chief financial officer
Apr 30, 2023	stankovich thomas	sold	-226	2.36	-96.00	chief financial officer
Mar 31, 2023	stankovich thomas	sold	-283	2.6	-109	chief financial officer

Which funds bought or sold RSLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	4,228	4,228	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-850	2,400	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	190	4,854	9,121	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-83.04	-16,508	2,364	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	40.64	204	5,492	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	4,248	4,248	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-18,195	-	-%
May 14, 2024	Qube Research & Technologies Ltd	reduced	-20.00	-51.00	74.00	-%
May 13, 2024	FMR LLC	sold off	-	-	-	-%
May 13, 2024	XTX Topco Ltd	new	-	2,267	2,267	-%

Are Funds Buying or Selling RSLS?

Are funds buying RSLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RSLS

No. of Funds

Unveiling ReShape Lifesciences Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 17, 2024	schneid yair	525%	2,461,000	SC 13G
Mar 17, 2023	matthew joseph nachtrab revocable trust 2014	27.7%	133,853	SC 13D
Feb 15, 2023	foley & lardner/ fa	27.7%	133,853	SC 13D
Feb 14, 2023	armistice capital, llc	4.99%	25,395	SC 13G/A
Feb 15, 2022	armistice capital, llc	9.99%	1,973,807	SC 13G/A
Feb 14, 2022	interwest partners x lp	0%	6,250	SC 13G/A
Jun 22, 2021	armistice capital, llc	0%	0	SC 13D/A

Recent SEC filings of ReShape Lifesciences Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 09, 2024	S-3	S-3
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to ReShape Lifesciences Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

ReShape Lifesciences Inc. News

Latest updates

ReShape Lifesciences Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.9%	1,944,000	1,982,000	2,155,000	2,254,000	2,287,000	3,110,000	2,798,000	2,892,000	2,440,000	3,142,000	3,708,000	3,529,000	3,221,000	4,211,000	3,602,000	1,702,000	780,000	787,000	333,000	386,000	1,775,000
Gross Profit	-36.8%	1,165,000	1,842,000	1,288,000	1,194,000	1,224,000	1,600,000	2,101,000	1,883,000	1,218,000	1,776,000	2,135,000	2,153,000	2,284,000	2,273,000	2,281,000	837,000	239,000	160,000	-79,000	-293,000	543,000
Operating Expenses	-9.7%	3,375,000	3,737,500	5,168,000	5,170,000	6,855,000	18,293,000	14,402,000	11,127,000	9,331,000	39,292,500	16,554,000	5,842,000	4,541,000	5,063,000	4,453,000	3,835,000	5,150,000	5,135,000	3,663,000	6,120,000	8,643,000
S&GA Expenses	-27.1%	1,019,000	1,398,000	1,791,000	2,177,000	2,182,000	2,157,500	2,605,000	4,636,000	4,694,000	1,527,500	3,246,000	4,298,000	1,250,000	29,000	1,160,000	831,000	3,893,000	3,643,000	2,489,000	4,332,000	6,204,000
R&D Expenses	-34.5%	484,000	739,000	542,000	581,000	453,000	462,000	583,000	747,000	745,000	270,000	1,425,000	103,000	571,000	898,000	859,000	465,000	1,257,000	1,492,000	1,174,000	1,788,000	2,439,000
EBITDA Margin	0.2%	-1.29	-1.29	-2.62	-3.32	-3.66	-4.09	-5.94	-5.87	-5.15	-4.62	-1.47	-1.48	-1.71	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	296,000	-	-	-	-	-	19,000	137,000	358,000	205,000
Income Taxes	-54.8%	14,000	31,000	3,000	4,000	14,000	-49,500	-400,000	9,000	30,000	-297,000	-30,000	28,000	25,000	-82,500	-39,000	-50,000	-	-	-	-	-
Earnings Before Taxes	-30.7%	-2,179,000	-1,667,000	-3,531,000	-3,489,000	-2,648,000	-16,525,000	-12,549,000	-9,435,000	-8,085,000	-37,546,000	-17,164,000	-3,861,000	-4,849,000	-	-5,218,000	-3,654,000	-	-	-	-	-
EBT Margin	0.2%	-1.30	-1.31	-2.67	-3.37	-3.71	-4.15	-6.00	-5.93	-5.20	-4.66	-1.49	-1.50	-1.71	-	-	-	-	-	-	-	-
Net Income	-29.2%	-2,193,000	-1,698,000	-3,534,000	-3,493,000	-2,662,000	-16,469,000	-12,186,000	-9,444,000	-8,115,000	-37,249,000	-17,134,000	-3,889,000	-4,874,000	-8,061,000	-5,179,000	-3,604,000	-5,261,000	-4,913,000	-3,706,000	-6,767,000	-8,290,000
Net Income Margin	0.2%	-1.31	-1.31	-2.67	-3.33	-3.68	-4.11	-5.94	-5.91	-5.18	-4.64	-2.31	-1.51	-1.71	-	-	-	-	-	-	-	-
Free Cashflow	15.7%	-2,072,000	-2,457,000	-2,780,000	-6,662,000	-5,061,000	-2,829,000	-5,273,000	-6,422,000	-7,378,000	-3,426,000	-7,800,000	-2,188,000	-1,961,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-22.8%	8,231	10,663	7,827	11,852	16,352	11,142	26,485	40,357	45,623	52,531	90,790	120,013	17,343	37,061	11,962	13,873	19,229	20,393	24,657	19,199	32,368
Current Assets	-23.3%	7,895	10,296	7,399	10,544	15,231	9,911	13,257	19,171	23,311	29,938	37,273	65,303	12,794	8,944	9,031	10,775	15,570	18,235	22,349	17,021	29,912
Cash Equivalents	-44.4%	2,479	4,459	1,449	4,567	8,983	3,855	6,245	11,544	15,460	22,815	29,293	40,213	1,946	3,007	1,907	1,576	8,915	2,985	19,380	13,513	24,684
Inventory	-7.3%	3,467	3,741	3,204	3,268	3,493	3,611	4,171	4,226	3,998	3,003	3,206	2,894	-	2,244	-	-	1,408	1,936	2,048	2,107	1,860
Net PPE	-10.0%	54.00	60.00	70.00	659	672	698	896	887	1,371	1,454	1,602	1,588	891	584	982	1,055	2,159	1,081	1,117	1,038	1,222
Goodwill	-	-	-	-	-	-	-	-	-	-	1,900	22,950	23,520	-	-	-	-	-	-	-	-	-
Liabilities	-7.6%	3,697	4,000	4,744	5,114	8,594	7,481	7,532	9,581	8,664	8,197	11,478	61,881	7,245	22,573	6,040	6,695	8,157	4,544	4,592	10,812	25,850
Current Liabilities	-6.8%	3,519	3,777	4,469	4,404	7,602	7,481	7,532	9,209	8,170	7,530	10,336	60,496	6,863	11,605	5,050	5,599	7,188	3,977	3,905	10,090	25,031
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	430	430	430	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	19,952
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	430	430	430	-	-	-	-	-
Shareholder's Equity	-32.0%	4,534	6,663	3,083	6,738	7,758	3,661	18,953	30,776	36,959	44,334	79,312	58,132	12,708	14,488	17,083	19,153	21,568	24,107	20,065	8,376	6,518
Retained Earnings	-0.3%	-637,767	-635,574	-633,876	-630,342	-626,849	-624,187	-607,718	-595,532	-586,088	-577,973	-540,724	-523,590	-188,900	-514,827	-183,439	-181,879	-177,700	-172,430	-167,500	-163,811	-157,044
Additional Paid-In Capital	0.0%	642,374	642,302	637,050	637,172	634,697	627,935	626,739	626,380	623,118	622,399	620,125	581,823	199,019	529,435	189,353	189,049	188,755	188,271	187,574	172,162	163,538
Shares Outstanding	0.0%	23,457	23,457	3,453	3,452	2,649	519	451	386	371	357	172	91.00	79.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,074	-	-	-	10,658	-	-	-	37,324	-	-	-	4,300	-	-	-	16,600	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	15.7%	-2,072	-2,457	-2,780	-6,662	-5,061	-2,829	-5,273	-6,422	-7,378	-3,426	-7,800	-2,188	-1,961	-1,762	-976	-998	-4,814	-4,879	-3,989	-4,356	-9,642
Share Based Compensation	-34.5%	72.00	110	216	218	222	240	-1.50	1,489	719	2,256	10,234	-364	101	298	259	292	470	683	659	536	1,105
Cashflow From Investing	-	-	-	-	-3.00	-7.00	-79.00	-33.00	18.00	2.00	-3,067	-89.00	5,130	-119	-2,160	-148	244	-326	-150	-24.00	-1.00	2,531
Cashflow From Financing	-100.0%	-	5,461	-338	2,250	10,201	638	3.00	-	-	-	-3,033	35,332	1,000	5,069	1,500	4,506	-	-296	9,880	-6,814	10,608

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RSLS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations
Revenue	$ 1,944	$ 2,287
Cost of revenue	779	1,063
Gross profit	1,165	1,224
Operating expenses:
Sales and marketing	1,019	2,182
General and administrative	1,872	4,220
Research and development	484	453
Total operating expenses	3,375	6,855
Operating loss	(2,210)	(5,631)
Other expense (income), net:
Interest (income) expense, net	(9)	5
Gain on changes in fair value of liability warrants	(21)	(2,965)
(Gain) loss on foreign currency exchange, net	24	(21)
Other	(25)	(2)
Loss before income tax provision	(2,179)	(2,648)
Income tax expense	14	14
Net loss	$ (2,193)	$ (2,662)
Net loss per share - basic and diluted:
Net loss per share - basic (in dollars per share)	$ (0.09)	$ (1.56)
Net loss per share - diluted (in dollars per share)	$ (0.09)	$ (1.56)
Shares used to compute basic net loss per share (in shares)	23,457,127	1,708,141
Shares used to compute diluted net loss per share (in shares)	23,457,127	1,708,141

RSLS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,379	$ 4,459
Restricted cash	100	100
Accounts and other receivables (net of allowance for doubtful accounts of $458 and $804, respectively)	1,566	1,659
Inventory	3,467	3,741
Prepaid expenses and other current assets	383	337
Total current assets	7,895	10,296
Property and equipment, net	54	60
Operating lease right-of-use assets	226	250
Deferred tax asset, net	27	28
Other assets	29	29
Total assets	8,231	10,663
Current liabilities:
Accounts payable	1,314	1,689
Accrued and other liabilities	1,930	1,814
Warranty liability, current	163	163
Operating lease liabilities, current	112	111
Total current liabilities	3,519	3,777
Operating lease liabilities, noncurrent	127	151
Common stock warrant liability	51	72
Total liabilities	3,697	4,000
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 23,457,090 and 23,457,047 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	23	23
Additional paid-in capital	642,374	642,302
Accumulated deficit	(637,767)	(635,574)
Accumulated other comprehensive loss	(96)	(88)
Total stockholders' equity	4,534	6,663
Total liabilities and stockholders' equity	8,231	10,663
Series C convertible preferred stock
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized: Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at March 31, 2024 and December 31, 2023

About ReShape Lifesciences Inc.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

CEO	Mr. Paul F. Hickey
WEBSITE	reshapelifesciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	40

ReShape Lifesciences Inc. Frequently Asked Questions

What is the ticker symbol for ReShape Lifesciences Inc.? What does RSLS stand for in stocks?

RSLS is the stock ticker symbol of ReShape Lifesciences Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ReShape Lifesciences Inc. (RSLS)?

As of Fri May 17 2024, market cap of ReShape Lifesciences Inc. is 4.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RSLS stock?

You can check RSLS's fair value in chart for subscribers.

What is the fair value of RSLS stock?

You can check RSLS's fair value in chart for subscribers. The fair value of ReShape Lifesciences Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ReShape Lifesciences Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RSLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ReShape Lifesciences Inc. a good stock to buy?

The fair value guage provides a quick view whether RSLS is over valued or under valued. Whether ReShape Lifesciences Inc. is cheap or expensive depends on the assumptions which impact ReShape Lifesciences Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RSLS.

What is ReShape Lifesciences Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RSLS's PE ratio (Price to Earnings) is -0.39 and Price to Sales (PS) ratio is 0.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RSLS PE ratio will change depending on the future growth rate expectations of investors.